No Data
Promising Outlook for Lexicon Pharmaceuticals' LX9211 as a Novel Treatment for Diabetic Peripheral Neuropathic Pain
Lexicon Pharmaceuticals (LXRX) Gets a Hold From Needham
9 Health Care Stocks With Whale Alerts In Today's Session
H.C. Wainwright Maintains Lexicon Pharmaceuticals(LXRX.US) With Buy Rating, Maintains Target Price $4
Lexicon Announces Virtual Webcast on LX9211 for Diabetic Peripheral Neuropathic Pain
Here's Why Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Is Among the Best Diabetes Stocks to Buy Under $10
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Lnova : Oh wait fda rejected?
Lnova :
Jaguar8 OP Lnova : CRL
Lnova Jaguar8 OP : Gotcha. But Lex is discontinuing it? They are scrapping it?
Jaguar8 OP Lnova : I think that was their decision after the CRL.
View more comments...